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Background:  Symptomatic heart failure (HF) has a prevalence of 30% in patients with atrial fibrillation (AF). Patients with HF are older 
and frailer, have more comorbidity and are at higher risk of both stroke and bleeding, compared with younger patients. We investigated the 
efficacy and safety of novel oral anticoagulants (NOAC) in patients with AF and HF, in a meta-analysis of all the recent phase III warfarin 
comparison trials.
methods:  MEDLINE, Cochrane, ISI Web of Science and SCOPUS databases were searched for articles about NOAC treatment in 
patients with AF until September 2014. Study inclusion criteria were: randomization to NOAC or warfarin; report of at least one outcome 
among stroke/systemic embolism (SSE), major or total or intracranial bleeding or CV death in the subgroup of patients with HF and AF. 
Meta-analysis was performed to assess the influence of treatments on outcomes.
results:  4 phase III, randomized trials (ARISTOTLE, ENGAGE-AF, RE-LY, ROCKET-AF) comparing NOAC versus warfarin in patients 
with AF, and including 26,384 subjects with AF and HF [median age 70 years (IQR: 68-72), 36% females, median follow-up 2 years 
(IQR:1.8-2.3)], were included in the meta-analysis. NOAC, compared to warfarin, significantly reduced the risk of SEE by 14.4% (RR:0.856 
[CI:0.756 to 0.968]; p=0.014, i2=0%), major bleeding by 23.2% (RR:0.768 [95% CI:0.682 to 0.865]; p<0.001, i2=0%) and intracranial 
bleeding by 44.9% (RR:0.551 [CI:0.387 to 0.785]; p<0.001, i2=53%). NOACs had a similar effect to warfarin on the risk of total bleeding 
(RR:0.881 [CI:0.760 to 1.023]; p=0.096, i2=88%) and CV death (RR:0.926 [CI:0.838 to 1.024]; p=0.133, i2=0%).
conclusion:  In AF patients with HF, NOACs, compared to warfarin, significantly reduced the risk of SSE, major and intracranial bleeding.
